71.31
Insmed Inc stock is traded at $71.31, with a volume of 632.14K.
It is up +2.28% in the last 24 hours and down -1.36% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$69.73
Open:
$69.92
24h Volume:
632.14K
Relative Volume:
0.29
Market Cap:
$12.99B
Revenue:
$381.03M
Net Income/Loss:
$-1.01B
P/E Ratio:
-11.99
EPS:
-5.95
Net Cash Flow:
$-789.25M
1W Performance:
+5.61%
1M Performance:
-1.36%
6M Performance:
-1.52%
1Y Performance:
+29.55%
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
INSM
Insmed Inc
|
71.31 | 12.39B | 381.03M | -1.01B | -789.25M | -5.95 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.13 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.66 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.54M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
83.84 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
488.96 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-13-25 | Initiated | Jefferies | Buy |
Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
Apr-23-24 | Initiated | Truist | Buy |
Feb-15-24 | Initiated | Wolfe Research | Outperform |
Dec-08-23 | Initiated | Wells Fargo | Overweight |
Nov-20-23 | Resumed | JP Morgan | Overweight |
Jul-26-23 | Initiated | Guggenheim | Buy |
Dec-09-22 | Initiated | Mizuho | Buy |
Dec-07-22 | Initiated | Barclays | Overweight |
Nov-18-22 | Initiated | BofA Securities | Buy |
Apr-27-22 | Initiated | Goldman | Buy |
Dec-06-21 | Initiated | JP Morgan | Overweight |
Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
Oct-19-21 | Resumed | Morgan Stanley | Overweight |
Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Dec-17-20 | Initiated | Berenberg | Buy |
Oct-12-20 | Resumed | Stifel | Buy |
Sep-03-19 | Initiated | Goldman | Buy |
Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
Jan-02-19 | Initiated | Canaccord Genuity | Buy |
Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Jul-23-18 | Initiated | Goldman | Neutral |
Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
Mar-21-18 | Initiated | Morgan Stanley | Overweight |
Jan-18-18 | Initiated | Credit Suisse | Neutral |
Sep-05-17 | Reiterated | Evercore ISI | Outperform |
Aug-17-17 | Initiated | Evercore ISI | Outperform |
Jul-11-17 | Initiated | Robert W. Baird | Outperform |
Mar-15-16 | Initiated | Stifel | Buy |
Nov-09-15 | Downgrade | UBS | Buy → Neutral |
Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
Jun-09-15 | Initiated | Citigroup | Neutral |
Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Insmed To Present at the 2025 Goldman Sachs Annual Global Health - GuruFocus
Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference - marketscreener.com
Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference – Company Announcement - Financial Times
Insmed’s SWOT analysis: rare disease biotech stock shows promise amid challenges - Investing.com
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis - marketscreener.com
Insmed (INSM) Highlights Promising Brensocatib Trial Results at - GuruFocus
Insmed (INSM) Highlights Promising Brensocatib Trial Results at ATS 2025 | INSM Stock News - GuruFocus
Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study - Yahoo Finance
Captrust Financial Advisors Sells 631 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World
Mercer Global Advisors Inc. ADV Acquires New Position in Insmed Incorporated (NASDAQ:INSM) - Defense World
HC Wainwright Issues Optimistic Outlook for Insmed Earnings - Defense World
INSMED Executives Sell Shares to Satisfy Tax Obligations - TradingView
Jefferies Financial Group Initiates Coverage on Insmed (NASDAQ:INSM) - Defense World
Jefferies Initiates Coverage of Insmed (BIT:1INSM) with Buy Recommendation - Nasdaq
Insmed Incorporated (INSM): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
Jefferies Initiates Coverage of Insmed (BMV:INSM) with Buy Recommendation - Nasdaq
Jefferies sets $105 target on Insmed stock with Buy rating By Investing.com - Investing.com Nigeria
Insmed at Bank of America 2025 Healthcare Conference: Strategic Pipeline Focus - Investing.com
Jefferies Initiates Coverage on INSM with a Buy Rating and $105 PT | INSM Stock News - GuruFocus
Jefferies Initiates Coverage of Insmed (LSE:0JAV) with Buy Recommendation - Nasdaq
Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Jefferies Initiates Coverage of Insmed (INSM) with Buy Recommendation - Nasdaq
Jefferies Initiates Coverage on Insmed With Buy Rating, $105 Price Target - marketscreener.com
Jefferies sets $105 target on Insmed stock with Buy rating - Investing.com
Insmed (NASDAQ:INSM) Given Buy Rating at HC Wainwright - Defense World
Insmed (INSM) Gains Buy Rating from Jefferies with Promising Out - GuruFocus
Insmed (INSM) Receives Reaffirmed Buy Rating from HC Wainwright - GuruFocus
Analyst Expectations For Insmed's Future - Benzinga
Insmed Incorporated (NASDAQ:INSM) Given Consensus Rating of “Buy” by Analysts - Defense World
UBS Group Cuts Insmed (NASDAQ:INSM) Price Target to $109.00 - Defense World
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates - MSN
Analysts Are Updating Their Insmed Incorporated (NASDAQ:INSM) Estimates After Its First-Quarter Results - Yahoo Finance
Insmed Incorporated (NASDAQ:INSM) Q1 2025 Earnings Call Transcript - Insider Monkey
Insmed (INSM) Receives Slight Price Target Adjustment by UBS | I - GuruFocus
UBS Maintains Buy Rating, Lowers Price Target for Insmed (INSM) - GuruFocus
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates - TradingView
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
Is Insmed Incorporated (INSM) the Best Cancer Stock to Invest in for Long-Term Gain? - Insider Monkey
Insmed (INSM) Receives Slight Price Target Adjustment by UBS | INSM Stock News - GuruFocus
RBC Trims Price Target on Insmed to $99 From $100, Keeps Outperform Rating - marketscreener.com
Insmed: Q1 Earnings Snapshot - Greenwich Time
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus
Insmed’s Earnings Call: Strong Growth and Optimistic Outlook - TipRanks
Insmed Q1 2025 Earnings Call Transcript - MarketBeat
Transcript : Insmed Incorporated, Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Earnings call transcript: Insmed Q1 2025 shows mixed results with slight EPS miss - Investing.com
Insmed Q1 Net Loss Widens, Revenue Increases; 2025 Revenue Guidance Maintained - marketscreener.com
Insmed (INSM) Reports Q1 Revenue Surpassing Expectations and Awaits Key Approvals | INSM Stock News - GuruFocus
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):